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Abstract Mutation analysis of retinal candidate genes is
performed as part of an ongoing research to identify the
causative genetic defect in South African families with
retinal degenerative disorders (RDDs). A translational
research protocol has been established whereby probands
are counseled and given their molecular genetic results to
take back to other family members, who can then request
individual diagnostic testing. A Thr17Met mutation of the
rhodopsin gene was identified in a Caucasian South African
family with autosomal dominant retinitis pigmentosa.
Patients with this mutation appear to benefit from treatment
using oral vitamin A supplementation. This family has been
informed that a molecular diagnosis is available; however,
one individual has refused testing and none of the younger
generation has shown interest in receiving molecular results
or genetic counseling. Adapting the established protocol for
the translation of RDD research results and contacting
mutation positive individuals may be justifiable in light of
the potential benefit of therapy.
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Introduction
Retinitis pigmentosa (RP) is a group of diseases character-
ized by photoreceptor cell death in the retina and
subsequent vision loss. Symptoms include night blindness,
followed by peripheral vision loss and decreasing visual
fields [1]. Total blindness occurs in 30% of cases [1, 2].
Approximately 65% of RP is nonsyndromic, and of these
cases approximately 30% show autosomal dominant Men-
delian inheritance.
Autosomal dominant retinitis pigmentosa (adRP) can be
classified into two main clinical types. In individuals with
type 1 adRP, onset of symptoms occurs early (in the first
decade of life). In individuals with type 2 adRP, onset of
symptoms begins later (in the second or third decade of
life) and can vary within or between families, with
asymptomatic mutation carriers being reported [3]. There
are currently 17 different genes implicated in causing adRP.
Mutations in the rhodopsin gene are causative of approx-
imately 27% of adRP [1].
A research project was initiated at the Division of
Human Genetics at the University of Cape Town in 1990
to investigate retinal degenerative disorders (RDD) in
South Africa. The goal of this ongoing research is to
identify the causative genetic mutation of each family in
the RDD DNA database to facilitate clinical and genetic
management and future therapeutic intervention. Once a
mutation has been identified in a family, the research re-
sults are translated into a diagnostic service where diag-
nostic, predictive, carrier, prenatal, and pre-implantation
testing can be offered [4]. The amount of information,
which can be given regarding prognosis of disease, poten-
tial therapies, and eligibility for treatment trials, however,
depends on how well the causative gene and/or mutation
has been characterized.
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This study has been approved by the Research Ethics
Committee of the Faculty of Health Sciences, University of
Cape Town (UCT). Informed consent has been obtained
from subjects, and the study complies with the Declaration
of Helsinki (2000). We certify that all applicable institu-
tional and governmental regulations concerning the ethical
use of human volunteers were followed during this
research.
Mutation analysis was performed across the entire
coding sequence of the rhodopsin gene (RHO) in a cohort
of 47 affected, unrelated individuals with adRP. Peripheral
blood samples were obtained and genomic DNA was
isolated from white blood cells, using standard methods.
DNA from each individual was subjected to PCR amplifi-
cation and single-stranded conformational polymorphism
analysis (SSCP), using previously published primers [5].
All samples exhibiting variant SSCP profiles were charac-
terized by direct sequencing using the ABI Prism™ 377
automated sequencer (Applied Biosystems, USA), accord-
ing to manufacturers instructions.
One pathogenic mutation, c.50C>T (which encodes a
Thr17Met amino acid change) was identified in RHO exon
1 of an affected Caucasian proband. The Thr17Met
mutation creates a BstX I restriction enzyme site, therefore
a restriction enzyme digest protocol was optimized to create
an accurate, reliable diagnostic assay. The enzyme digest
was performed as follows: 15 μl RHO exon 1 PCR product,
1U BstXI (Roche Diagnostics, South Africa) and 1× SuRE/
Cut Buffer were incubated in a reaction volume of 20 μla t
45°C for 16 hours. Products of the restriction enzyme digest
were separated on a 3% agarose gel containing ethidium
bromide and visualized under ultraviolet light. The enzyme
digest was performed on all available samples from
relatives to ensure co-segregation of the variant with
disease in this family.
The research results were translated into a diagnostic
service according to a protocol established by a team,
which included genetic counselors, medical scientists, co-
principal investigators, and a clinical coordinator. The
established protocol is as follows:
1. Patients (individuals and/or families) are recruited for
research, and DNA from the proband is screened for
mutations.
2. If a mutation is detected in the proband, DNA from
the family is tested for that mutation (at this point
the proband will have been retested to confirm the
screening result, and the family members will have
been tested once).
3. The proband is contacted, counseled, and given the
molecular results to take back to the rest of the family.
4. If a family member requests an individual diagnostic
result, DNA from that individual will be retested after
appropriate counseling, depending on whether the
individual is symptomatic or asymptomatic. Ideally
two tests are performed on two different DNA samples,
isolated on different days. This is assessed on a case by
case basis, depending on risk status and pretest
counseling.
5. A report is written and the results are delivered, after
discussion by the management team.
Results
A well-characterized rhodopsin mutation, Thr17Met, was
identified in a Caucasian South African family. The family
pedigree is shown in Fig. 1 and clinical information of
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Fig. 1 Pedigree of the South
African family with adRP
caused by a Thr17Met mutation
of rhodopsin. In the pedigree
shown, standard symbols are
used—squares represent males
and circles represent females.
Shaded symbols indicate affect-
ed individuals, and a symbol
with a line through it indicates
that the individual is deceased.
Individual 63.2 (III: 5) was the
proband, and individuals 63.1–
63.5 are individuals from whom
blood was taken for research
purposes
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with the Thr17Met mutation appear to benefit from
treatment using oral vitamin A supplementation. Individual
63.4 (IV: 1) has been using vitamin A supplementation for
7 years, which has reportedly slowed the progression of his
disease (personal communication).
This family was informed that individual molecular
testing is now available; however, one affected individual,
63.5 (IV: 3), has refused testing and none of the younger
generation (V) has shown interest in receiving molecular
results or genetic counseling.
Discussion
Patients with the Thr17Met mutation generally have a good
prognosis: with a relatively later onset and milder pheno-
type of type 2 adRP [6, 7]. Thr17Met causes an abnormally
folded rhodopsin protein that accumulates in the endoplas-
mic reticulum (ER) of the photoreceptor cell [7, 8]. The
accumulation of misfolded protein in the cell results in
impairment of the ubiquitin–proteosome system, which is
vital for cellular regulation, and this leads to cytotoxicity
and apoptosis [8, 9]. A potential therapy for patients with
this type of misfolding mutation is the use of retinoids as
chaperones to improve folding of the protein [9].
In transgenic mice with the Thr17Met mutation, vitamin
A supplementation was shown to increase the availability
of 11-cis retinal in the retina, binding of which increased
the stability of mutant rhodopsin protein, allowed correct
localization of the protein and slowed the rate of visual
decline [10]. Oral vitamin A supplementation in patients
with RP has also been shown to reduce the rate of retinal
degeneration [11]. Close medical supervision is required
when using Vitamin A supplementation, however, as
excessive intake can potentially cause liver toxicity as well
as reduced bone density [12]. In addition, Vitamin A has
been shown to cause teratogenic effects during pregnancy
and may interact with anticonvulsant agents [13].
Patients participating in the RDD research project at the
University of Cape Town are motivated by the hope of a
cure for themselves or their family members [14]. The
identification of an RDD mutation in a family generally
means that a molecular diagnosis can be given for members
of that family. Patients report that this causes no significant
improvement to their day-to-day living. In the case of
Thr17Met, mutation carriers can also be given a more
accurate disease prognosis, and offered possible therapeutic
intervention. Of the 1181 families currently participating in
the research program, this is the only case where disease
intervention is immediately possible. This particular family
can be offered the benefit of molecular-based management
and disease intervention; however, affected individual 63.5
(IV: 3) has refused testing and none of the younger
generation has made use of the diagnostic service available.
This case highlights a concern regarding the responsibility
oftheresearcher/counselor:shouldindividual63.5(IV:3)and
the younger members of the family be actively pursued or
shouldtheonusbeonthemtoinitiatemoleculartesting?Ithas
beensuggestedthatanethicaldutytoreturnindividualgenetic
results exists, and that the right of an individual not to receive
information can be overridden when there is evidence that the
information may benefit others [15]. Vitamin A supplemen-
tation may indeed prove beneficial to the mutation positive
individuals in the youngest generation of this family
(including the daughter of individual 63.5). In this case, the
right of individual 63.5 (IV: 3) not to receive his molecular
results may be less important than the benefit from
therapeutic intervention with Vitamin A supplementation in
the younger generation. Adapting the established protocol
for the translation of RDD research results, and contacting
these individuals may therefore be justifiable.
It has been suggested that genetic testing for RDDs may be
associated with a psychological benefit; the fact that “some-
Table 1 Clinical information
of individuals from the family
with Thr17Met in rhodopsin
Individual Mutation Current Age Age of Onset Other Clinical
Information
63.1 None Deceased
63.2 Heterozygous
RHO Thr17Met
Deceased
63.3 Not tested Deceased 16 Nightblindness noticed when young,
subsequent central vision loss, very
poor vision at age 77.
63.4 Heterozygous
RHO Thr17Met
66 20 Diffuse RP, night blindness, restricted
visual field and myopia, loss of
central vision in left eye at age 64.
Vitamin A supplementation from
1999–2006, vision reported to be
stable during this time
63.5 Refused testing 64
j ocul biol dis inform (2008) 1:55–58 57 57thing is being done” fosters hope and optimism on the part of
the patient [16]. In this case, unlike for the majority of
RDDs, something can actually be done to decelerate the
progression of disease in members of this family. The case
presented here serves to highlight the challenges faced by
researchers, as well as the benefits provided to the patients,
when translational research is undertaken.
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